1-16 of 16
Yiping Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT246: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer

Ziming Li, Xiaomin Dang, Dingzhi Huang, Shi Jin, Weiwei Li, Jianhua Shi, Xicheng Wang, Yiping Zhang, Zhengbo Song, Junping Zhang, Wu Zhuang, Xuewen Liu, Liyan Jiang, Xiangjiao Meng, Mingfang Zhao, Jianying Zhou, Liangming Zhang, Pingli Wang, Hui Luo, Junquan Yang, Shundong Cang, Xiang Wang, Jing Wang, Jiuwei Cui, Yan Yu, Zhihong Zhang, Junguo Lu, Weihua Yang, Gaofeng Li, Jifeng Feng, Dongqing Lv, Lin Wu, Yong Fang, Yan Wang, Yanqiu Zhao, Baoshan Cao, Wei Zhu, Zhixiang Zhuang, Qingshan Li, Mingxi Wang, Huan Zhou, Xiaorong Dong, Sheng Hu, Jian Fang, Yihong Zhang, Wenjia Wang, Ziyong Xiang, Zhe Shi, Ling Zhang, Shun Lu
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT246.
https://doi.org/10.1158/1538-7445.AM2024-CT246
Published: 05 April 2024
View article titled, Abstract CT246: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer
Journal Articles

Abstract CT235: RNA-seq molecular subtypes and gene expression signatures in the phase 3 IMpower151 study of 1L bevacizumab + pemetrexed/paclitaxel ± atezolizumab in metastatic NSCLC

Caicun Zhou, Charlie Sun, Stacey Huang, Xiaorong Dong, Gongyan Chen, Zhehai Wang, Xianghua Wu, Yu Yao, Yiping Zhang, Ying Cheng, Hongming Pan, Xiaodong Zhang, Jiuwei Cui, Lifeng Wang, Xi Chen, Xiaoling Li, Ziping Wang, Qiming Wang, Jianxing He, Mengzhao Wang, Li Qian, Habib Hamidi, Shanshan Li, Marcus Ballinger, David S. Shames, Minu Srivastava
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT235.
https://doi.org/10.1158/1538-7445.AM2024-CT235
Published: 05 April 2024
View article titled, Abstract CT235: RNA-seq molecular subtypes and gene expression signatures in the phase 3 IMpower151 study of 1L bevacizumab + pemetrexed/paclitaxel ± atezolizumab in metastatic NSCLC
Journal Articles

Abstract CT126: An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation

Daniel Tan, Koichi Goto, Herbert HF Loong, Tsung-Ying Yang, Shirish Gadgeel, Erminia Massarelli, Gennaro Daniele, Xiuning Le, Yuki Shinno, Haruyasu Murakami, Tomohiro Sakamoto, Jose C. Ruffinelli, Shun Lu, Yiping Zhang, Tae Min Kim, Barbara J. Brennan, Chunlin Chen, Miranda Joosten, Zebin Wang, Su-Fen Pu, Weichao Bao, Martin Kornacker, Roberta Ferraldeschi, Paolo Grassi, Boon Cher Goh
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT126.
https://doi.org/10.1158/1538-7445.AM2023-CT126
Published: 14 April 2023
View article titled, Abstract CT126: An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation
Journal Articles

Abstract CT505: Phase I study of D-1553 to assess safety and efficacy in patients with non-small cell lung cancer (NSCLC) harboring KRASG12C mutation

Hong Jian, Zhenbo Song, Yiping Zhang, Kunyan Li, Nong Yang, Melissa Moore, Pingli Wang, Yanqiu Zhao, Yi Gong, Craig Underhill, Sang-We Kim, Cheng-Ta Yang, Ziyong Xiang, Zhe Shi, Ling Zhang, Yaolin Wang, Shun Lu
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT505.
https://doi.org/10.1158/1538-7445.AM2022-CT505
Published: 15 June 2022
View article titled, Abstract CT505: Phase I study of D-1553 to assess safety and efficacy in patients with non-small cell lung cancer (NSCLC) harboring KRAS<sup>G12C</sup> mutation
Journal Articles

Abstract CT538: Tepotinib + gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT

Chong Kin Liam, Azura Rozila Ahmad, Te-Chun Hsia, Jianying Zhou, Dong-Wan Kim, Ross Andrew Soo, Ying Cheng, Shun Lu, Sang Won Shin, James Chih-Hsin Yang, Yiping Zhang, Jun Zhao, Rolf Bruns, Andreas Johne, Yi-Long Wu
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT538.
https://doi.org/10.1158/1538-7445.AM2022-CT538
Published: 15 June 2022
View article titled, Abstract CT538: Tepotinib + gefitinib in patients with <em>EGFR</em>-mutant NSCLC with <em>MET</em> amplification: Final analysis of INSIGHT
Journal Articles

Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)

Shun Lu, Yongfeng Yu, Jianya Zhou, Koichi Goto, Xingya Li, Jun Sakakibara-Konishi, Kazumi Nishino, Tanaka Kentaro, Lin Wu, Xuhong Min, Wei Zhang, Dingzhi Huang, Yongqian Shu, Chengzhi Zhou, Min Li, Xiaorong Dong, Chong Bai, Lu Li, Jiuwei Cui, Li Zhang, Lejie Cao, Xiaoling Li, AiMin Zang, Haruki Kobayashi, Yiping Zhang, Yan Yu, Xiuwen Wang, Terufumi Kato, Shoichiro Yamamoto, Yuki Shinno, Xiaoyan Lin, Yanqiu Zhao, Yanping Hu, Qitao Yu, Ziping Wang, Masahiro Kodani, Jian Fang, Jialei Wang, Meiqi Shi, Diansheng Zhong, Wen Dong, Hiroshi Tanaka, Yasuto Yoneshima, Minghui Sun, Jun Zhou, Qiuxia Wu, Meng Li
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT034.
https://doi.org/10.1158/1538-7445.AM2022-CT034
Published: 15 June 2022
View article titled, Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)
Journal Articles

Abstract CT170: D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156)

Shun Lu, Yiping Zhang, Guojun Zhang, Jianying Zhou, Shundong Cang, Ying Cheng, Gang Wu, Peiguo Cao, Dongqing Lv, Xiangming Jin, Hong Jian, Chengshui Chen, Guanming Jiang, Panwen Tian, Kai Wang, Hui Zhao, Gongyan Chen, Qun Chen, Cuimin Ding, Junquan Yang, Renhua Guo, Guoping Sun, Bin Wang, Liyan Jiang, Wu Zhuang, Zhe Liu, Jian Fang, Yunpeng Liu, Jian Zhang, Jun Chen, Yueyin Pan, Qitao Yu, Min Zhao, Jiuwei Cui, Dianming Li, Tienan Yi, Zhuang Yu, Yan Yang, Yan Zhang, Xiuyi Zhi, Yunchao Huang, Rong Wu, Liangan Chen, Aimin Zang, Lejie Cao, Qingshan Li, Xiaoling Li, Yong Song, Donglin Wang, Shucai Zhang
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT170.
https://doi.org/10.1158/1538-7445.AM2021-CT170
Published: 01 July 2021
View article titled, Abstract CT170: D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156)
Journal Articles

Abstract 2997: Longitudinal circulating tumor DNA (ctDNA) analysis predicts response and reveals the resistance mechanisms of ensartinib in ALK+ NSCLC patients (pts) progressed on crizotinib: Updated analysis of a phase II clinical trial

Yunpeng Yang, Jie Huang, Tao Wang, Jianya Zhou, Jing Zheng, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Li Mao, Giovanni Selvaggi, Larry Zhu, Shanshan Xiao, Li Zhang
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 2997.
https://doi.org/10.1158/1538-7445.AM2020-2997
Published: 15 August 2020
View article titled, Abstract 2997: Longitudinal circulating tumor DNA (ctDNA) analysis predicts response and reveals the resistance mechanisms of ensartinib in ALK+ NSCLC patients (pts) progressed on crizotinib: Updated analysis of a phase II clinical trial
Journal Articles

Abstract CT114: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study

Yi-Long Wu, Shun Lu, Ying Cheng, Caicun Zhou, Jie Wang, Tony Mok, Li Zhang, Haiyan Tu, Lin Wu, Jifeng Feng, Yiping Zhang, Alexander Valeriercich Luft, Jianying Zhou, Zhiyong Ma, You Lu, Chengping Hu, Yuankai Shi, Christine Baudelet, Zoe Li, Jianhua Chang
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT114.
https://doi.org/10.1158/1538-7445.AM2018-CT114
Published: 01 July 2018
View article titled, Abstract CT114: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study
Journal Articles

Abstract 4678: Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations

Robert S. Meehan, Alice P. Chen, Geraldine O’Sullivan Coyne, Shivaani Kummar, Jiuping Ji, Rasa Vilimas, Lamin Juwara, Robert J. Kinders, Katherine Ferry-Galow, Deborah Wilsker, Yiping Zhang, Angie B. Dull, Tony Navas, Lihua Wang, Ralph E. Parchment, James H. Doroshow
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4678.
https://doi.org/10.1158/1538-7445.AM2017-4678
Published: 01 July 2017
View article titled, Abstract 4678: Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations
Journal Articles

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

Junko Murai, Shar-yin N. Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H. Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier
Journal: Cancer Research
Cancer Res (2012) 72 (21): 5588–5599.
https://doi.org/10.1158/0008-5472.CAN-12-2753
Published: 31 October 2012
View article titled, Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Open the PDF for Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

Shivaani Kummar, Alice Chen, Jiuping Ji, Yiping Zhang, Joel M. Reid, Matthew Ames, Lee Jia, Marcie Weil, Giovanna Speranza, Anthony J. Murgo, Robert Kinders, Lihua Wang, Ralph E. Parchment, John Carter, Howard Stotler, Larry Rubinstein, Melinda Hollingshead, Giovanni Melillo, Yves Pommier, William Bonner, Joseph E. Tomaszewski, James H. Doroshow
Journal: Cancer Research
Cancer Res (2011) 71 (17): 5626–5634.
https://doi.org/10.1158/0008-5472.CAN-11-1227
Published: 30 August 2011
View article titled, Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
Open the PDF for Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas in another window
Includes: Supplementary data
Journal Articles

Abstract 4527: Pharmacodynamic and pathway analysis of three presumed inhibitors of poly (ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201

Jiuping Ji, Maxwell P. Lee, Mitsutaka Kadota, Yiping Zhang, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 4527.
https://doi.org/10.1158/1538-7445.AM2011-4527
Published: 15 April 2011
View article titled, Abstract 4527: Pharmacodynamic and pathway analysis of three presumed inhibitors of poly (ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201
Journal Articles

Abstract 1763: Quantitative gamma-H2AX immunoassay for pharmacodynamic monitoring anticancer cytotoxic agents

Yiping Zhang, Ralph Parchment, Joseph Tomaszewski, James Doroshow, Jay Ji
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 1763.
https://doi.org/10.1158/1538-7445.AM10-1763
Published: 15 April 2010
View article titled, Abstract 1763: Quantitative gamma-H2AX immunoassay for pharmacodynamic monitoring anticancer cytotoxic agents
Journal Articles

Abstract #5456: Correlation between inhibition of the activity of poly(ADP-ribose) polymerase (PARP) in human peripheral blood mononuclear cells (PBMCs) and tumor biopsies following treatment with ABT-888, an inhibitor of PARP

Shivaani Kummar, Larry Rubinstein, Robert Kinders, Jiuping Ji, Ralph Parchment, Martin Gutierrez, Anthony Murgo, Alice Chen, Sonny Khin, Yiping Zhang, Dwight Simmons, Mary Ann Yancey, Deborah Allen, Yvonne Horneffer, Lamin Juwara, Richard Chang, Gary Gordon, Joseph Tomaszewski, James Doroshow
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 5456.
Published: 01 May 2009
View article titled, Abstract #5456: Correlation between inhibition of the activity of poly(ADP-ribose) polymerase (PARP) in human peripheral blood mononuclear cells (PBMCs) and tumor biopsies following treatment with ABT-888, an inhibitor of PARP
Journal Articles

A validated assay for gamma-H2AX as a pharmacodynamic biomarker of response to DNA damage

Jay Jiuping Ji, Ravithat Putvatana, Yiping Zhang, Christophe Redon, Olga Sedelnikova, Sherry Yang, Yves Pommier, William Bonner, Robert Kinders, Ralph Parchment, Melinda Hollingshead, Jennifer Low, Anthony Murgo, Joseph Tomaszewski, James Doroshow
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 4027.
Published: 01 May 2007
View article titled, A validated assay for gamma-H2AX as a pharmacodynamic biomarker of response to DNA damage